4B Technologies (4B Tech) is a biotech company specializing in the development of transformative medicines for nervous system diseases.
CNS diseases represent one of the fastest growing and most impactful health threats, affecting hundreds of millions of patients worldwide. Despite of tremendous efforts and progresses in decades, effective and safe therapeutics for major CNS illness are scarce and remain an urgent unmet need.
4B Tech was founded with its mission to focus on innovative medicines for neurodegenerative and other neurological disorders. With deep insights in neurosciences and CNS drug discovery, we have developed a strategic framework to enhance probability of success by systematically tackling key challenges faced in CNS drug discovery and development, including human centric strategy, CNS drug delivery, translational disease model, and biomarker-integrated trial design. By leveraging cutting edge sciences/technologies and exceptional clinical resources, 4B Tech, along with academic and industrial partners, is advancing a pipeline for innovative medicines to validate their therapeutic potentials in the clinic. Our aspiration is to make a meaningful positive difference to patients suffering from CNS diseases.
Dr. Lu is a world renowned neuroscientist, with interests covering neurodevelopment, synaptic plasticity, model animals, and nervous system diseases. Prior to founding 4B Technologies, he has served many leadership positions, including Executive Dean of Tsinghua Medical School, Vice President of GlaxoSmithKline R&D, and Associate Director of a trans-NIH Translational Medicine program. He has received many honors including NIH Director's Award, Mathilde Solowey Award, and was named by Thomson Reuters in 2014 as one of World's Highly Cited Researchers, the only one in the neuroscience category named in China. His current research focuses on disease mechanisms, translation and clinical research, and drug development.
Dr. Lu obtained his Bachelor Degree from East China Normal University, his Ph.D. from Cornell University and post-doctorial training at Rockefeller University.
Dr. Guan has over 27 years of R&D and leadership experience in pharmaceutical industry with a focus on diseases of the central nervous system. Prior to founding 4B Technologies, he served as vice president, head of neurodegeneration DPU at GlaxoSmithKline (GSK), leading a multi-disciplinary global team and an end-to-end portfolio of novel drugs for Alzheimer’s and Parkinson’s diseases. Prior to GSK, Dr. Guan had an 18-year tenure at Merck Research Labs (MRL), where he focused effort on drug discovery and development for metabolic and CNS diseases with increasing responsibilities. He also served as founding executive team member of AMP-AD, an international consortium for Alzheimer’s disease.
Dr. Guan obtained his medical training from Fudan University School of Medicine, China, his Ph.D. in Biochemistry from Indiana University School of Medicine and post-doctorial trainings at Stanford University and Howard Hughes Medical Institute, USA. He has published his scientific and drug R&D findings in 60+ papers in leading journals.
Dr. Su has more than 20 years of research and operation experience in novel drug discovery and preclinical research in biopharmaceutical industry. She acknowledged with strategic mental acuity and solid track record in biologics development for metabolic diseases, autoimmune and cancer immunotherapy. Before joining 4B Technologies, Dr. Su was CVP and President of Novo Nordisk Research Center China, mainly responsible for developing site vision, setting strategic direction and overseeing daily operations of a world class research center. As a member of Novo Nordisk global research management team, she worked closely with senior leaders in Denmark, the US and the UK to drive business priorities, raise the innovation level in R&D and create comprehensive pipelines. Dr. Su served as Head of Strategy and Operations at GSK R&D China, she had contributed to the development of NS pipeline as well as GSK R&D China strategy, led the external alliance function and established an external research collaboration portfolio with a focus on Neuroscience.
Dr. Su received a Bachelor Degree in Medicine from School of Medicine, Peking University and Ph.D. in Pharmacology from New York University Medical Center. She also holds an MBA in Corporate management program from Peking University
Dr. Liu has more than 20 years of pharmaceutical industry experience focusing on clinical research and development of innovative new drugs, especially CNS products, in MNCs and domestic pharmaceutical companies. Before joining the industry, he had over 16 years of academic and clinical practice experience as an Attending Physician and a Research Professor in the 6th Hospital of BMU until 1998. Before joining 4B Technologies, he was the Vice President at CSPC Pharmaceutical Group Ltd. heading the medical team. Before that, he was the vice president of R & D and President of Clinical Research Hub in Sichuan Kelun Pharmaceutical Co., Ltd, set up the clinical development teams in China and USA. Before that, he was the President R&D for Ausa Pharmaceuticals for 9 years, focusing on cerebrocardiovascular diseases. Dr. Liu also has extensive research and management experiences in UCB, Eli Lilly & Company mainly focusing on neuroscience field.
Dr. Liu had a M.D. degree and had his Ph.D. education jointly in Beijing Medical University and Padova University Italy.
Dr. Lu has accumulated 18 years research experience in neuroscience with focus on pain, schizophrenia, and neurodegenerative diseases. He has over 13 years of R&D experience in pharmaceutical industry with expertise in preclinical development and translational science. Before joining 4B Technologies, Dr. Lu was Vice President of Translational Medicine (TM) in Joyo Pharma, establishing and leading the team to successfully deliver three INDs. While working in Novartis and GSK R&D, Dr. Lu gained rich experience in drug discovery including novel target validation and candidate selection. Before that Dr. Lu successfully established and managed in vivo pharmacology platforms for CNS in WuXi AppTec and ChemPartner.
Dr. Lu obtained his Bachelor Degree in Medicine and Master Degree in Pharmacology from Shanxi Medical University, and his Ph.D. in Neuropharmacology from SIMM, Chinese Academy of Sciences.
Chen Lv has 15 years of R&D and strategic planning experience in drug discovery. Before joining 4B technologies, she had a 10-year tenure at GSK’s China R&D Center, where she performed drug discovery work for high priority projects. She has participated in more than twenty projects with a focus on diseases of the nervous system (including small molecules and biologics), and successfully advanced several projects into pre-clinical & clinical stages. She has extensive experience in managing cross-functional teams and maximizing organizational effectiveness to achieve on-time project deliveries.
Chen obtained an MS degree in Biochemistry from Zhejiang Sci-Tech University, and a BS in Molecular biology from Inner Mongolia University.
Xiuming Liu is responsible for HR strategy and operation support. She brings over 12 years’HR professional experience mainly in the healthcare industry. She has expertise in team establishment, organizational culture building, leadership development, talent management, performance and compensation management, policy and system set up.
Xiuming obtained a Bachelor Degree from Nanjing University Of Finance & Economics.
Jingjing Wang is responsible for overall finance work. She has accumulated working experience of 14 years in an overall finance role as an auditor and accountant. She has extensive experience in building financial systems, establishing and optimizing financial policies, minimizing financial risk and monitoring day-to-day financial operations.
Jingjing obtained a Bachelor Degree from Jiang Nan University with major in accounting.